314 related articles for article (PubMed ID: 25350645)
1. Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Duh MS; Lefebvre P
J Med Econ; 2015 Feb; 18(2):113-25. PubMed ID: 25350645
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Sabapathy S; Neslusan C; Yoong K; Teschemaker A; Johansen P; Willis M
J Popul Ther Clin Pharmacol; 2016; 23(2):e151-68. PubMed ID: 27463416
[TBL] [Abstract][Full Text] [Related]
3. Cost efficiency of canagliflozin versus sitagliptin for type 2 diabetes mellitus.
Ektare VU; Lopez JM; Martin SC; Patel DA; Rupnow MF; Botteman MF
Am J Manag Care; 2014 Oct; 20(10 Suppl):S204-15. PubMed ID: 25495002
[TBL] [Abstract][Full Text] [Related]
4. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
[TBL] [Abstract][Full Text] [Related]
6. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
[TBL] [Abstract][Full Text] [Related]
7. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
[TBL] [Abstract][Full Text] [Related]
10. Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Lefebvre P; Pilon D; Robitaille MN; Lafeuille MH; Chow W; Pfeifer M; Duh MS
Curr Med Res Opin; 2016 Jun; 32(6):1151-9. PubMed ID: 27115475
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
[TBL] [Abstract][Full Text] [Related]
12. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
14. Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Inagaki N; Goda M; Yokota S; Maruyama N; Iijima H
Adv Ther; 2015 Nov; 32(11):1085-103. PubMed ID: 26530268
[TBL] [Abstract][Full Text] [Related]
15. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Schernthaner G; Gross JL; Rosenstock J; Guarisco M; Fu M; Yee J; Kawaguchi M; Canovatchel W; Meininger G
Diabetes Care; 2013 Sep; 36(9):2508-15. PubMed ID: 23564919
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
[TBL] [Abstract][Full Text] [Related]
17. Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.
Tanton D; Duh MS; Lafeuille MH; Lefebvre P; Pilon D; Zhdanava M; Emond B; Inman D; Bailey RA
Curr Med Res Opin; 2018 Jun; 34(6):1099-1115. PubMed ID: 29468896
[TBL] [Abstract][Full Text] [Related]
18. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
Bailey RA; Vijapurkar U; Meininger G; Rupnow MF; Blonde L
Clin Ther; 2015 May; 37(5):1045-54. PubMed ID: 25795432
[TBL] [Abstract][Full Text] [Related]
19. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Wysham CH; Lefebvre P; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Chow W; Pfeifer M; Duh MS
BMC Endocr Disord; 2017 Jun; 17(1):32. PubMed ID: 28595617
[TBL] [Abstract][Full Text] [Related]
20. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Patel CA; Bailey RA; Vijapurkar U; Meininger G; Blonde L
BMC Health Serv Res; 2016 Aug; 16(a):356. PubMed ID: 27495291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
